Exenatide once weekly: clinical outcomes and patient satisfaction by Jose, Biju et al.
© 2010 Jose et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Patient Preference and Adherence 2010:4 313–324
Patient Preference and Adherence Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
313
Review
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/PPA.S7494
exenatide once weekly: clinical outcomes  
and patient satisfaction
Biju Jose1
Abd A Tahrani1,2
Milan K Piya1,2
Anthony H Barnett1,2
1Department of Diabetes and 
endocrinology, Heart of england NHS 
Foundation Trust, Birmingham, UK; 
2School of Clinical and experimental 
Medicine, University of Birmingham, 
Birmingham, UK
Correspondence: Abd A Tahrani 
The MiDRU, Birmingham Heartlands 
Hospital, Birmingham B9 5SS, UK 
Tel +44 7801549960 
email a.a.tahrani@bham.ac.uk
Background: Type 2 diabetes mellitus (T2DM) is a complex disorder in which interactions 
between environmental and genetic factors result in the development of insulin resistance (in 
most cases) and progressive pancreatic β-cell failure. The currently available oral anti-diabetes 
treatments are effective as monotherapy; however, due to the progressive decline in β-cell 
function, most patients will require the use of combination therapy and eventually insulin to 
reach glycemic targets. These therapeutic options are not without undesirable side effects such 
as weight gain and hypoglycemia. Furthermore, T2DM is associated with impaired quality of 
life (QOL) and poor compliance with treatment. Hence, there is a need for anti-diabetes agents 
that result in sustained improvements in glycemic control without hypoglycemia or weight 
gain and have a positive impact on patients QOL and thereby hopefully improve compliance. 
Incretin-based therapy is the latest addition to anti-diabetes treatments which addresses some 
of the shortcomings of older treatments.
Aims: To review the evidence for the use of exenatide once-weekly.
Methods: We have searched Medline using the terms “exenatide”, “exenatide once-weekly”, 
and “exenatide LA”.
Results: Exenatide once-weekly is an incretin mimetic that is currently undergoing phase 3 
clinical trials, and has been shown to improve glycemic parameters (HbA1c and fasting and 
postprandial glucose levels), with low risk of hypoglycemia, causes weight loss, and use was 
associated with improvements in patient satisfaction which might have a positive impact on 
treatment compliance.
Conclusions: Exenatide once-weekly is effective, well tolerated in patients with T2DM and 
should be a useful addition to the available range of anti-diabetes treatments.
Keywords: diabetes mellitus, incretins, exenatide once-weekly, quality of life, treatment 
satisfaction
Introduction
Type 2 diabetes mellitus (T2DM) is a global epidemic with an estimated worldwide 
prevalence of 6% (246 million people) in 2007 that is forecasted to rise to 7.3% 
(380 million) by 2025.1,2 The health, social, and economic burden of T2DM is great;3–5 
it continues to pose a major challenge to healthcare provision around the world.
The development of insulin resistance (IR) and pancreatic β-cell dysfunction due to 
various environmental and genetic factors results in onset of T2DM.6,7 Despite obesity 
being the single most important contributor to IR, most obese insulin-resistant individu-
als do not develop T2DM8,9 because their β-cells are capable of producing sufficient 
insulin to maintain euglycemia.9–13 This suggests that the failure of β-cells to secrete 
sufficient insulin to overcome IR is the key step in the development and progression Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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of T2DM.6,7,9,10 Pancreatic α-cell dysfunction manifesting as 
non-suppressed glucagon secretion in the presence of hyper-
glycemia is also manifest in patients with T2DM.14
Several pharmacological agents have been developed 
to treat patients with T2DM. They either improve insulin 
resistance (biguanides, glitazones), stimulate insulin secre-
tion from the β-cell (sulfonylureas, metaglinides), or decrease 
glucose absorption from the gut (α-glucosidase inhibitors).15 
The initial improvements in glycemic control observed with 
these agents as monotherapy are not sustained because of the 
progressive nature of the disease due to the continuing decline 
in β-cell function.9,16 This often necessitates the use of com-
bination therapy and eventually insulin. Furthermore, current 
agents may be associated with undesirable side effects includ-
ing gastrointestinal (metformin, α-glucosidase   inhibitors), 
weight gain (sulfonylureas, metaglinides, glitazones, and 
insulin), and hypoglycemia (sulfonylureas, metaglinides, 
and insulin).17 These side effects may contribute to further 
worsen the already impaired health-related quality of life 
(QOL) found in patients with T2DM18 and may contribute to 
poor compliance common in this group of patients.19
Treatment acceptability and adherence are particularly 
important in the management of T2DM. A systematic review 
showed that many patients took less than their prescribed dose 
of insulin and/or oral anti-diabetes medications20 and that a 
substantial proportion of patients had difficulty in dealing 
with various elements of the chronic disease management, 
particularly adhering to a strict drug regimen.21,22
Taking the above into account, there is a need for new 
pharmacological agents that are well tolerated with sustain-
able impact on glycemic control, and with very low risk of 
hypoglycemia, cause weight loss (or at least no weight gain) 
and thereby encourage patient adherence to therapy. Incretin-
based therapy is the latest class of anti-diabetes medications 
to become available and addresses some of the shortcomings 
of conventional anti-diabetes treatments. Incretin-based ther-
apy can be given either orally (dipeptidyl peptidase-4 (DPP-4) 
inhibitors) or via a subcutaneous   injection (  glucagon-like 
peptide (GLP-1) analogues/  mimetics). They improve glyce-
mic control with favorable impact on weight and low risk of 
hypoglycemia (apart from when used with sulfonylureas).23 
In addition, animal studies have shown that some of these 
agents improve β-cell survival,23 which if true in humans 
might result in a more sustained impact on glycemic control. 
GLP-1 analogs/mimetics are given in once- or twice-daily 
dosing regimes. However, other drugs are in development 
in this category that require administration once weekly 
or even less frequently.23 Such a dosing regimen might be 
highly acceptable to patients and encourage compliance 
with treatment.
In this article, we aim to review the available data regard-
ing the once-weekly use of exenatide in the management of 
T2DM and the potential patient considerations for the use of 
this drug. Further details regarding incretin-based therapies 
are not within the scope of this article and can be found 
elsewhere.24–27
Incretins
Incretins are hormones that are released from the gut in response 
to ingestion of food.28 The incretin effect was first described 
in 1964, when it was observed that the insulin response to oral 
glucose challenge was substantially higher than to an intrave-
nous glucose load.29 The incretin response accounts for at least 
50% of insulin secretion in healthy individuals.30
Glucose-dependent insulinotropic polypeptide (GIP) was 
the first incretin to be isolated and characterized.31,32 It is a 
42 amino acid peptide secreted in the bioactive form from 
the K-cells in duodenum and jejunum in response to inges-
tion of carbohydrates and lipids.33 The second incretin to be 
isolated was GLP-1, which is cleaved from pro-glucagon 
and secreted from the L-cells in the distal ileum and colon.33 
GLP-1 levels are reduced in patients with T2DM, unlike GIP 
levels which are maintained.34
Both GIP and GLP-1 facilitate glucose-dependent insulin 
secretion through their action on pancreatic β-cells. GLP-1 
increases insulin gene transcription as well as all the steps of 
insulin biosynthesis.35 In addition, GLP-1 results in glucose-
dependent glucagon suppression, delays gastric emptying, 
increases satiety, and possibly reduces insulin resistance.36,37 
There is also evidence that GLP-1 increases β-cell mass in 
animal studies.38
GLP-1 secretion is reduced in patients with T2DM.39 
Although there is a blunting of GLP-1 secretory response in 
these patients, their response to exogenous GLP-1 is intact.23 
A continuous 6-hour intravenous infusion of GLP-1 in the 
fasting state, leading to GLP-1 levels 2–3 times higher than 
normally seen after meals, resulted in lowering of glucose and 
glucagon levels, with increases in insulin secretion without 
any hypoglycemic events in patients with poorly controlled 
T2DM.40 Subcutaneous GLP-1 was also shown to have a 
similar glucose-lowering effect when administered pre-meal 
in patients with T2DM.41
Incretins are rapidly metabolized by the enzyme DPP-4, 
and thus have extremely short half-lives (GIP , 2 minutes 
and GLP-1 5–7 minutes).42,43 The short half-life of these natu-
rally occurring incretins limited their clinical use. This led Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
315
exenatide once weekly
to the development of various modifications of the amino 
acids of GLP-1, rendering them DPP-4   resistant. Exenatide 
(Byetta®; Eli Lilly), a synthetic analog of   exendin-4, was the 
first-in-class incretin mimetic.   Liraglutide   (Victoza®; Novo 
Nordisk), an analog of human GLP-1, is a fatty acid   derivative 
of GLP-1 that has been approved for   clinical use more 
recently. There are several long-acting once-weekly prepa-
rations currently in phase 3 clinical   trials – exenatide once-
weekly (Byetta®; Eli Lilly), albiglutide (  GlaxoSmithKline) 
and taspoglutide (Ipsen and Roche), all of which show 
promising results. Research has also targeted developing 
inhibitors of the DPP-4 enzyme. The currently available 
DPP-4 inhibitors are sitagliptin (Januvia®; Merck & Co), 
vildagliptin (Galvus®; Novartis) and   saxagliptin   (Onglyza®; 
Bristol-Myers Squibb and Astra-Zeneca).   Alogliptin (Takeda) 
and linagliptin (Ondero®; Boehringer Ingelheim) are cur-
rently undergoing phase 3 clinical trials.
Exenatide, a synthetic version of the naturally occurring 
salivary peptide isolated from the Gila monster (Heloderma 
suspectum), is a partial structural analog of human GLP-1 
and has 53% amino acid sequence homology with human 
GLP-1.44 It contains a glycine at position 2, in contrast to 
human GLP-1, which has an alanine at position 2, thus 
making the molecule DPP-4 resistant, in turn conferring a 
longer half-life.44 Exenatide has a half-life of 3.3–4.0 hours 
and clinical effects lasting for up to 8 hours.45–47 Exenatide 
treatment results in significant reductions in fasting plasma 
glucose (FPG) and post-prandial glucose (PPG) in patients 
with T2DM.48–51 In addition, it results in slowing of gastric 
emptying (which contributes to the reductions in PPG),52 
appetite suppression53 and weight loss.54
The AC2993 Diabetes Management for Improving 
Glucose Outcomes (AMIGO) trials were three 30-week 
randomized, triple-blind, placebo-controlled, multicenter 
trials that had similar design and examined the impact of 
exenatide treatment on glycemic control in patients with 
T2DM. 48,55,56 They enrolled subjects aged 16–75 years who 
were poorly controlled on metformin and/or sulfonylurea 
with HbA1c 7.5%–11%. In the AMIGO trials, patients 
were randomized to placebo, exenatide 5 µg or exenatide 
10 µg while continuing metformin and/or sulfonylurea. By 
week 30, exenatide 10 µg resulted in mean HbA1c reduc-
tion of −0.8% ± 0.1% to −0.9 ± 0.1% compared with a 
−0.16% ± 0.1% to 0.08% ± 0.1% in placebo.55 The effects 
of exenatide on glycemic control appeared to be sustainable 
as reductions achieved at 30 weeks (−1.0% ± 0.1%) were 
maintained at 82 weeks57 and 3 years58 in the open-label 
extensions of the AMIGO trials.
The open-label extensions of the AMIGO trial also 
showed that exenatide treatment promotes progressive weight 
loss up to 82 weeks (−2.1 ± 0.3 kg versus −4.0 ± 0.3 kg for 
exenatide 10 µg week 30 versus week 82 respectively).57,59 
Furthermore, a subset of patients who had 3.5 years of 
exenatide exposure had reductions in triglycerides of 12% 
(P = 0.0003); LDL-C decreased by 6% (P , 0.0001), and 
HDL-C increased by 24% (P , 0.0001).59
Exenatide is generally well tolerated long term, but the 
most commonly reported adverse events (AEs) (mostly in the 
first few weeks of treatment) are nausea, vomiting,   diarrhea, 
headache, dizziness, and dyspepsia.60 In a recent meta-
analysis, exenatide was associated with a significant increase 
in the proportion of patients experiencing hypoglycemia in 
placebo-controlled trials (OR: 2.92 (1.49–5.75), P = 0.002). 
This excess, however, was only observed when exenatide was 
combined with sulfonylureas.61 Concerns about acute pancrea-
titis have been raised in patients using exenatide. However, 
a 1-year follow-up study of patients who were initiated on 
exenatide, sitagliptin, glyburide, or metformin showed the risk 
of acute pancreatitis to be   comparable between the cohorts.62 
Nonetheless, the FDA has changed the labeling on the drug 
to warn about possibility of acute pancreatitis particularly 
in susceptible patients, based on post-marketing analysis 
s  howing 30 reported cases of pancreatitis in 2007 and 6 cases 
of necrotizing hemorrhagic pancreatitis in 2008.60 The FDA 
also warns that exenatide should not be used in patients with 
severe renal impairment (creatinine clearance , 30 mL/min) 
or end-stage renal failure, and should be used with caution 
in those with renal transplant or moderate renal impairment 
(creatinine clearance 30–50 mL/min).60
Although exenatide is relatively well tolerated and effec-
tive in improving glycemic control with favorable impact on 
weight and low risk of hypoglycemia, the main drawback is 
that it needs to be administered by twice-daily injections. 
As a result, the development of exenatide once-weekly is 
now in progress.
Exenatide once-weekly
Chemistry
Exenatide once-weekly uses a sustained release drug 
delivery system. Molecules of exenatide are encapsulated 
in injectable microspheres of poly (D, L lactic-co-glycolic 
acid), a biodegradable polymeric matrix commonly used in 
extended release preparations.63 This poly-lactide-glycolide 
and exenatide microsphere suspension allows gradual drug 
delivery at a controlled rate by diffusion and erosion of the 
microspheres.63,64Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Pharmacokinetics
Mean plasma concentration of exenatide once-weekly (0.8 or 
2 mg) reached clinically significant levels (at which exenatide 
lowers blood glucose) by week 2 in a 15-week phase 2 study 
of 45 adults (60% men, 60% Caucasians) whom glycemic 
control was suboptimal (HbA1c 8.5% ± 1.2%) with metformin 
and/or life-style changes.64,65 By week 6, exenatide once-
weekly attained a maximum concentration higher than that 
attained by a single injection of exenatide 10 µg (a steady state 
concentration of 232 pg/mL versus 211 pg/mL).59 Six weeks 
after stopping treatment, the serum concentration of exenatide 
once-weekly declined steadily to insignificant levels.64
In a randomized, double-blind, parallel study in Japanese 
patients with T2DM (59% men, aged 58 ± 9 years), the AUC 
(0–8 hours) of exenatide once-weekly on day 1 was 187.6 
(133.7–263.3) pg * h/mL and 405.6 (278.4–590.8) pg * h/mL 
for 0.8 mg and 2 mg respectively.66 The Cmax on day 
1 was 64.3 (38.3–107.8) pg/mL for 0.8 mg and 137.3 
(74.6–252.6) pg/mL for 2 mg of exenatide once-weekly. 
  Geometric mean (90% CI) steady-state plasma concentrations 
were 81.2 (68.3–96.4) pg/mL and 344.5 (256.5–462.7) pg/mL 
with 0.8 mg and 2.0 mg respectively (Figure 1).66
The diabetes therapy utilization researching changes 
in A1c, weight, and other factors through intervention with 
Exenatide once-weekly (DURATION)-1 study (described 
below) showed that plateau concentrations of exenatide 
were achieved after 6–10 weeks of exenatide once-weekly 
with a geometric mean steady state plasma concentration of 
71.7 pmol/L.67
Clinical efficacy
impact on glycemic parameters
There are 3 published randomized controlled trials that 
assessed the impact of exenatide once-weekly on glycemic 
parameters (Table 1). Exenatide once-weekly produced sig-
nificant reductions in HbA1c, FPG, and PPG when used in 
drug-naïve patients or patients treated with one or more oral 
anti-diabetes therapy.64,66,67
The DURATION-1 study was a randomized,   open-label, 
non-inferiority study that compared exenatide 2.0 mg 
weekly to exenatide 10 µg twice daily in patients with 
T2DM. 303 patients were enrolled and 295 (53% men, 78% 
  Caucasians) were randomized.67 All patients underwent a 
3-day lead-in period with exenatide 5 µg twice daily, after 
which they were randomized to either exenatide 2.0 mg once-
weekly or exenatide 5 µg twice daily for 28 days, followed by 
exenatide 10 µg twice daily. Participants had a mean age of 
55 ± 10 years with a mean BMI of 35 ± 5 kg/m2. The   baseline 
anti-diabetes treatment included metformin (73%), sulfo-
nylurea (37%), and thiazolidinediones (16%) alone or in 
combination.67 By week 10, there were significantly greater 
reductions in HbA1c in the once-weekly group compared 
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with the twice-daily group, which continued to be the case 
until study end (week 30) (Table1). A greater proportion of 
patients randomized to exenatide once-weekly achieved target 
HbA1c # 7.0% (77% versus 61%; P = 0.0039). Exenatide 
once-weekly also resulted in greater reductions of FPG and 
2-hour PPG (measured during a mixed meal tolerance test) 
(Table 1).67
In another randomized, placebo-controlled, phase 2 trial, 
45 (60% male) drug-naïve or metformin-treated patients with 
T2DM were randomized to 2.0 mg or 0.8 mg exenatide once-
weekly or placebo.64 HbA1c reductions were apparent in both 
the exenatide once-weekly groups from week 3 onwards and 
continued to improve until study end (Table 1). 86% of the 
2.0 mg group and 36% of the 0.8 mg group achieved target 
HbA1c 7.0% or less compared with 0% in the placebo group.64 
In addition, by week 15, exenatide once-weekly (2.0 mg or 
0.8 mg) resulted in significant reductions in FPG and PPG 
(based on self monitored blood glucose profiles) compared 
with placebo.
Exenatide once-weekly was also examined in a Japanese 
population in a 10-week randomized, placebo-controlled, 
double-blind, parallel study in patients with T2DM 
  suboptimally controlled by life style and/or biguanide, 
sulfonylurea, thiazolidinedione, or combinations of these 
agents.66 Patients continued their baseline medications 
  during this study. Patients were randomized in a 1:1:1 ratio 
to   subcutaneous placebo once weekly, exenatide once weekly 
0.8 mg, or exenatide once weekly 2.0 mg.66 At week 10, there 
was significant reduction in HbA1c in the exenatide once-
weekly groups compared with placebo (Table 1). Similarly, 
FPG and PPG concentrations showed clinically relevant 
reductions in the exenatide once-weekly groups compared 
with placebo (Table 1).
The impact of exenatide once weekly seems to be sustain-
able up to 2 years following initiating treatment.68,69 In the 
open-label extension of the DURATION-1 trial, 258 patients 
entered the 22-week open-ended assessment phase (n = 128 
exenatide once weekly only; n = 130 switched from daily 
to once weekly exenatide).68 Exenatide once weekly main-
tained the HbA1c improvements through the 52 weeks 
(−2.0% [−2.1% to −1.8%]). Patients switching from daily 
to weekly exenatide achieved further HbA1c improvements, 
but both groups had a mean HbA1c of 6.6% at study-end. At 
week 52, 71% and 54% of all patients achieved an A1c , 7.0% 
and #6.5%, respectively.68 This glycemic improvement 
was achieved without any major hypoglycemia. A further 
open-label extension of the DURATION-1 trial involving 
135 patients who have completed 2 years treatment with 
2 mg exenatide once weekly showed that the initial improve-
ments in HbA1c were maintained at 2 years with 66% and 
42% of patients achieving an HbA1c #7.0% and #6.5%, 
respectively.69
impact on weight
Similar to exenatide twice-daily treatment, exenatide once 
weekly results in significant weight loss (Table 1). In the 
study by Kim et al exenatide once weekly 2 mg resulted in 
a weight loss of 3.8 ± 1.4 kg (mean ± SE) from baseline by 
week 15 (P , 0.05, compared with the placebo).64 In the 
DURATION-1 trial, the weekly exenatide treatment group 
had a weight change of −3.7 kg (SE 0.5) at week 30, which 
was comparable to the twice-daily exenatide treatment 
(−3.6 kg [SE 0.5]).67
However, in the Japanese study, exenatide once weekly 
resulted in a weight neutral effect, while the placebo group 
lost 1.6 kg (Table 1).66 This effect was seen in earlier exenatide 
twice daily studies in Japanese subjects.70 The authors hypoth-
esize that the leanness of the Japanese cohort could contribute 
to this apparent neutral effect on weight.
The impact of exenatide once weekly on weight seems 
to be sustainable. At 52 weeks, body weight was reduced 
by .4 kg.68 In the 2-year open-label extension of the 
DURATION-1 study, there was significant reduction in 
body weight from baseline (−3.6 ± 0.6 kg; 95% CI: −4.8 
to −2.3 kg) by 2 years.69
impact on cardiovascular risk factors
Exenatide once weekly resulted in significant reductions in 
lipids and blood pressure (Table 2).67
The 2-year open-label extension of the DURATION-1 
study reported that exenatide once weekly improved 
serum lipids (triglycerides: −18%, 95% CI −24% to 
−12%; total cholesterol: −0.25 ± 0.09 mmol/L, 95% CI 
−0.42 to −0.07 mmol/L). These subjects were also able to 
maintain a significant reduction in systolic blood pressure 
(−3.2 ± 1.2 mmHg; 95% CI −5.5 to −0.8 mmHg) throughout 
the treatment period.69
impact on glucagon and other incretin-related effects
Exenatide once weekly resulted in more glucagon suppression 
than exenatide twice daily.67 In the DURATION-1 study, glu-
cagon levels changed by −18⋅0 (SE: 2⋅9) ng/L (from a baseline 
of 103 (3⋅1) ng/L) and −6⋅4 (2⋅9) ng/L (from a baseline of 99⋅0 
(3⋅0) ng/L) for exenatide once weekly and exenatide twice daily 
respectively (P , 0.05).67 The impact of exenatide once weekly 
on satiety and gastric emptying has not been examined.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Adverse events
Hypoglycemia
There were no significant events of hypoglycemia reported 
with exenatide once weekly in the DURATION-1 study or 
its open-label extensions.67–69 In the Japanese study, patient-
reported hypoglycemia was reported in 2 patients. Both of 
these patients were on concomitant sulfonylurea therapy.66
In the earlier study by Kim et al patient-reported hypo-
glycemia was reported in 25% with exenatide once weekly 
0.8 mg, of which only one was confirmed with a blood glu-
cose level of 3.1 mmol/L and all were mild, and 0% in the 2.0 
mg group; patients in the placebo arm had no   hypoglycemia 
events.64
Other Aes
The common AEs are summarized in Table 3. Nausea was 
the most commonly reported side effect. Other AEs included 
vomiting, diarrhea, injection-site pruritus, and bruising. 
Elevated blood amylase levels were reported in 2 patients 
in the exenatide 0.8 mg once-weekly group, but these were 
not associated with any clinical symptoms of pancreatitis. 
Baseline to week 10 elevations in amylase levels did not 
reach significance in any of the groups, and no cases of 
pancreatitis were reported. There were no clinically relevant 
AEs relating to vital signs, ECG, or blood results. There were 
no withdrawals from the study due to AEs.
In the 2-year open-label extension of the DURATION-1 
study, mild nausea diminished over time, occurring in only 8% 
of patients during the open-ended treatment period compared 
with 26.4% patients during the 30-week study period.69
Overall, exenatide once weekly was well tolerated with 
no serious patient-reported AEs in any of the 3 published 
studies. Mild nausea and injection-site pruritus were com-
monly encountered. Incidences of hypoglycemia were mild. 
So far, no cases of acute pancreatitis have been reported in 
any of the studies.
Anti-exenatide antibodies
The development or presence of antibodies did not have any 
clinical effect on the incidence of hypoglycemia or change in 
HbA1c in any of the available studies.64,66,67 Kim et al reported 
that 67% of subjects receiving exenatide once weekly had 
anti-exenatide antibodies at week 15, but no association could 
be found with safety or efficacy in   individual patient profile.64 
DURATION-1 reported that anti-exenatide antibody levels 
were higher with exenatide once a week compared with twice-
daily exenatide (P = 0⋅0002); however, there were significant 
reductions in mean HbA1c over 30 weeks in patients with 
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negative, low titer (1/25 to 1/125), and high titer (.1/625) 
antibodies in the exenatide once-weekly group compared 
with twice daily (Figure 2).67 Anti-exenatide antibodies were 
present in 60.0% (6/10) and 77.8% (7/9) of patients in the 
exenatide once-weekly 0.8 mg and exenatide once-weekly 
2.0 mg groups, respectively, at any point during the Japanese 
study. But this did not have any clinical effect on hypoglycemia 
or HbA1c change (data not available).66
Ongoing clinical trials
DURATION-2, a head-to-head comparative study of 
exenatide once weekly against sitagliptin or pioglitazone is 
a 26-week, double-blinded, phase 3, superiority study involv-
ing 491 patients whose diabetes was suboptimally controlled 
on metformin. Preliminary results were presented at the 
  European Association for the Study of Diabetes annual meet-
ing in 2008 and American Diabetes Association   conference in 
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Figure 2 intention-to-treat subanalysis (N = 295) of change in HbA1c (least square mean (Se) by antibody status). Negative antibodies were not detectable in repeated 
analyses throughout the 30 weeks; low titer (#1/625) at any point during the 30 weeks; and high titer ($1/625) at any point during the 30 weeks; HbA1c reductions of −1.4% 
were observed in patients treated once a week in the high titer group. Reprinted from Drucker DJ, Buse JB, Taylor K. DURATiON-1: exenatide once weekly produces 
sustained glycemic control and weight loss over 52 weeks. The Lancet. 372:1240–1250, Copyright © 2008, with permission from elsevier.
Table 3 Most common Aes from the 3 published studies on exenatide once weekly
AE Kim et al64  Drucker et al67 Iwamoto et al66
2.0 mg Ex 
QW
0.8 mg Ex 
QW
Placebo  
QW
2.0 mg Ex 
QW
10 µg Ex 
BD
2.0 mg Ex 
QW
0.8 mg Ex 
QW
Placebo 
QW
Nausea 27% 19% 15% 26.4% 34.5% 33.3 0 0
vomiting – – – 10.8% 18.6% 11.1 0 10
Gastroenteritis/diarrhea 13% 19% 0% 13.5% 13.1% – – –
injection-site pruritus – – – 17.6% 1.4% 44.4 40 20
injection site bruising/induration 7% 13% 0% 4.7% 10.3% 88.9 90 60
Constipation  – – – 10.8% 6.2% – – –
Upper respiratory tract infection – – – 8.1% 17.2% – – –
Abbreviations: Ae, adverse event; ex, exenatide; Qw, once weekly; BD, twice daily.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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2009, yet to be published.71,72 HbA1c   reduction and weight loss 
was superior to the comparator arms; at 26 weeks the change 
in HbA1c was −1.55%, −0.92% and −1.23% for exenatide 
once weekly, sitagliptin 100 mg daily and pioglitazone 45 
mg daily, respectively. Weight change was −2.7 kg, −0.9 kg, 
and +3.2 kg respectively.71,72
DURATION-3 was another phase 3, 26-week, open-
label, superiority study involving 467 patients with T2DM 
who were suboptimally controlled on metformin and/or a 
sulfonylurea, comparing exenatide once weekly with insulin 
glargine. The results are still awaited, but a press release 
reports a greater reduction in HbA1c, weight loss, and fewer 
hypoglycemic episodes in the exenatide once-weekly group 
compared with insulin glargine.73
DURATION-4 is currently in progress, comparing 
exenatide once weekly to metformin, sitagliptin, and piogli-
tazone; DURATION-5 is also ongoing, comparing exenatide 
once weekly to exenatide twice daily. Several other compara-
tive trials are currently underway; details can be accessed 
from www.clinicaltrials.gov.74
Patient considerations
Diabetes imposes significantly on the patient’s and carer’s QOL, 
particularly considering the chronic and progressive nature of 
the disease, increasing treatment burden with time and multiple 
long-term complications and its attendant consequences, both 
financially and socially.5 Poor medication compliance is one of 
the major challenges for the success of treatment of conditions 
like diabetes and hypertension.75 Patient satisfaction and toler-
ability may have a decisive role in the use and choice of these 
new diabetes treatment options that will soon be available.76
The DURATION-1 study examined treatment satisfac-
tion using Diabetes Treatment Satisfaction Questionnaire 
(DTSQ). The researchers found that patients treated with 
exenatide once weekly reported a significant increase in 
treatment satisfaction from baseline compared with exenatide 
twice daily, despite having similar compliance in the 2 groups 
(injections received/injections planned (98%)).67
The treatment satisfaction and weight-related QOL in 
patients treated with exenatide once weekly was assessed in 
a randomized, multicenter, open-label study and involved 
295 patients randomized to exenatide once weekly or 
exenatide twice daily for 30 weeks.76 At study-end, patients 
receiving exenatide twice daily were switched to exenatide 
once weekly for a further 22 weeks. DTSQ and Impact of 
Weight on Quality of Life – Lite (IWQOL-Lite) were assessed 
at baseline, 30 weeks, and 52 weeks. Both groups showed 
statistically significant improvements in DTSQ   measures 
from baseline to week 30. At week 30,   between-group 
differences from baseline in DTSQs total scores were not 
statistically significant (5.17 ± 0.54 versus 3.97 ± 0.53; 
P = 0.09), but treatment satisfaction did improve more in 
the exenatide once-weekly arm for perceived hypoglycemia 
frequency (from 1.86 ± 0.15 to 1.42 ± 0.15; P = 0.03) and 
willingness to continue current treatment (from 1.43 ± 0.13 
to 0.99 ± 0.12; P = 0.01).76
In the group who switched from exenatide twice daily 
to exenatide once-weekly at 30 weeks, DTSQ total score 
improved significantly (1.16 ± 6.1; P = 0.037), as did 
treatment convenience (0.42 ± 1.6; P = 0.003), treatment 
  flexibility (0.39 ± 1.7; P = 0.012) and satisfaction with con-
tinuing treatment (0.24 ± 1.3; P = 0.048) by week 52.
There were no statistically significant differences in 
weight-related QOL (IWQOL-Lite) between the 2 treatment 
arms at week 30. Treatment satisfaction and QOL improved 
significantly from weeks 30 to 52 in those who switched the 
regimen at week 30, reporting further significant improve-
ment in physical function (2.13 ± 11.5; P = 0.04) and public 
distress (5.04 ± 11.2; P , 0.001) domains. Patients who 
continued on once-weekly treatment improved significantly 
from week 30 to week 52 for public distress (6.96 ± 13.2; 
P , 0.001).76
This study has several important highlights. Both 
exenatide twice daily and once weekly improved treatment 
satisfaction and weight-related QOL significantly. The fact 
that the effect was maintained over 52 weeks is encouraging 
and suggests that these effects may be durable and patients 
could benefit from the sustained clinical effects of the drug. 
There is some evidence that exenatide once-weekly therapy 
resulted in greater treatment satisfaction compared with 
exenatide twice daily, and patients who were on exenatide 
once weekly were more willing to continue treatment. This 
suggests that acceptance of exenatide once weekly may 
be more than for exenatide twice daily. This might be due 
to the ease of use and reduced frequency of injections.76 
  Furthermore, the efficacy of exenatide once weekly compared 
to exenatide twice daily and the reduction in the perceived 
frequency of hyperglycemia could also have contributed to 
the impact on treatment satisfaction.67
In the DURATION-2 study (described above), weight-
related QOL, psychological general wellbeing, diabetes 
treatment satisfaction, and general health status were assessed 
using the IWQOL-Lite, Psychological General Well-being 
(PGWB) index, DTSQ, and EQ-5D at baseline and week 26.77 
The exenatide once-weekly group experienced significant 
improvement in physical function, self-esteem, sexual life, 
public distress, work, and IWQOL total score compared with 
pioglitazone; however, there were no significant   differences Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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between exenatide once weekly and sitagliptin. Overall 
  treatment satisfaction improved significantly in the exenatide 
once-weekly group versus sitagliptin. Both exenatide 
once-weekly and sitagliptin groups experienced significant 
improvements in overall health status.
It is relevant to note that the recognised AEs of exenatide, 
both twice daily and once weekly, nausea and injection-site 
reactions did not deter patients from continuing with treat-
ment, nor did it affect their QOL.76 This suggests that these 
issues may not be significant obstacles to improving patient 
acceptance of this new modality of treatment.
Conclusion
Exenatide once weekly is a new agent for the treatment of 
patients with T2DM and is currently going through phase 3 
trials. Exenatide once weekly produce significant reduction in 
weight and glycemic parameters when compared with placebo 
or exenatide twice daily. These improvements were achieved 
with low risk of hypoglycemia and were sustainable up to 
2 years in extension trials. Furthermore, exenatide once-weekly 
treatment has been shown to be associated with improvements 
in patient satisfaction and QOL, which might have a positive 
impact on patient adherence and compliance with treatment, 
which needs further testing in real-world situations. The results 
of the other phase 3 trials are awaited with interest.
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